Brind.
  1. The FDA cleared the IND application for ZW251, a product of Zymeworks.

Zymeworks achieved FDA approval for its drug zanidatamab, while also announcing personnel and award news.

1 report, 1 independent Updated Jul 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Zymeworks achieved FDA approval for its drug zanidatamab, while also announcing personnel and award news.

Who's involved

What this event is mainly about
ZymeworksFDA

Keep exploring

Part of

The FDA cleared the IND application for ZW251, a product of Zymeworks. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireLife Sciences BC Announces 2025 Awards Winners, Honouring Excellence in Health Innovation VANCOUVER, British Columbia, July 10, 2025--(BUSINESS WIRE)--Life Sciences BC (LSBC) is pleased to announce t